R
SYNTHETIC COMMUNICATIONSV
7
[7] Brehme, M.; Voisine, C.; Rolland, T.; Wachi, S.; Soper, J. H.; Zhu, Y.; Orton, K.; Villella,
A.; Garza, D.; Vidal, M.; et al. A Chaperome Subnetwork Safeguards Proteostasis in Aging
and Neurodegenerative Disease. Cell Rep. 2014, 9, 1135–1150. DOI: 10.1016/
[8] Kalia, S. K.; Kalia, L. V.; McLean, P. J. Molecular Chaperones as Rational Drug Targets
for Parkinson’s Disease Therapeutics. CNS Neurol. Disord. Drug Targets. 2010, 9, 741–753.
€
ꢀ
[9] Karagoz, G. E.; Duarte, A. M. S.; Akoury, E.; Ippel, H.; Biernat, J.; Moran Luengo, T.;
Radli, M.; Didenko, T.; Nordhues, B. A.; Veprintsev, D. B.; et al. Hsp90-Tau Complex
Reveals Molecular Basis for Specificity in Chaperone Action. Cell. 2014, 156, 963–974.
[10] Pratt, W. B.; Gestwicki, J. E.; Osawa, Y.; Lieberman, A. P. Targeting Hsp90/Hsp70-Based
Protein Quality Control for Treatment of Adult Onset Neurodegenerative Diseases. Annu.
[11] Tukaj, S.; WeRgrzyn, G. Anti-Hsp90 Therapy in Autoimmune and Inflammatory Diseases:
A Review of Preclinical Studies. Cell Stress Chaperones. 2016, 21, 213–218. DOI: 10.1007/
[12] Khandelwal, A.; Crowley, V. M.; Blagg, B. S. J. Natural Product Inspired N-Terminal
Hsp90 Inhibitors: From Bench to Bedside? Med. Res. Rev. 2016, 36, 92–118. DOI:
[13] Neckers, L.; Workman, P. Hsp90 Molecular Chaperone Inhibitors: Are we There yet?
[14] Trepel, J.; Mollapour, M.; Giaccone, G.; Neckers, L. Targeting the Dynamic HSP90
Complex in Cancer. Nat. Rev. Cancer. 2010, 10, 537–549. DOI: 10.1038/nrc2887.
[15] Taipale, M.; Jarosz, D. F.; Lindquist, S. HSP90 at the Hub of Protein Homeostasis: emerg-
ing Mechanistic Insights. Nat. Rev. Mol. Cell Biol. 2010, 11, 515–528. DOI: 10.1038/
[16] Schopf, F. H.; Biebl, M. M.; Buchner, J. The HSP90 Chaperone Machinery. Nat. Rev. Mol.
[17] Pratt, W. B. The Role of Heat Shock Proteins in Regulating the Function, Folding, and
Trafficking of the Glucocorticoid Receptor. J. Biol. Chem. 1993, 268, 21455–21458.
ꢀ
[18] Csermely, P.; Schnaider, T.; SoTi, C.; Prohaszka, Z.; Nardai, G. The 90-kDa Molecular
Chaperone Family: Structure, Function, and Clinical Applications. A Comprehensive
[19] Da Silva, V. C. H.; Ramos, C. H. I. The Network Interaction of the Human Cytosolic
90 kDa Heat Shock Protein Hsp90: A Target for Cancer Therapeutics. J. Proteomics. 2012,
[20] Holzbeierlein, J.; Windsperger, A.; Vielhauer, G. Hsp90: A Drug Target? Curr. Oncol. Rep.
[21] Wawrzynow, B.; Zylicz, A.; Zylicz, M. Chaperoning the Guardian of the Genome. The
Two-Faced Role of Molecular Chaperones in p53 Tumor Suppressor Action. Biochim.
[22] Garg, G.; Khandelwal, A.; Blagg, B. S. J. Anticancer Inhibitors of Hsp90 Function: Beyond
[23] Soga, S.; Akinaga, S.; Shiotsu, Y. Hsp90 Inhibitors as anti-Cancer Agents, from Basic
Discoveries to Clinical Development. Curr. Pharm. Des. 2013, 19, 366–376. DOI: 10.2174/
[24] Hong, D. S.; Banerji, U.; Tavana, B.; George, G. C.; Aaron, J.; Kurzrock, R. Targeting the
Molecular Chaperone Heat Shock Protein 90 (HSP90): Lessons Learned and Future
[25] Khandelwal, A.; Kent, C. N.; Balch, M.; Peng, S.; Mishra, S. J.; Deng, J.; Day, V. W.; Liu,
W.; Subramanian, C.; Cohen, M.; et al. Structure-Guided Design of an Hsp90b